OncoGenex Technologies Inc.

We are a biopharmaceutical company committed to the development and commercialization of new cancer therapies that address treatment resistance in cancer patients. Our product candidates are being developed to block the production of specific proteins associated with the development of treatment resistance, which we believe will increase survival time and improve the quality of life for cancer patients. In response to many cancer therapies (including hormone ablation therapy, chemotherapy and radiation therapy), tumor cells become stressed and increase production of certain proteins. These proteins cause tumor cells to become resistant to the cancer therapies and promote the survival of tumor ( www.oncogenex.ca )